Macitentan

Endothelin Receptor Antagonist — CARDIOVASCULAR SYSTEM

Key facts

Macitentan is an ofp drug in the Endothelin Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Endothelin Receptor Antagonists. DrugCentral lists 5 molecular targets, including EDNRA, EDNRB and DRD3. Recorded indications include Pulmonary arterial hypertension.

• Approval status: ofp (first approved 2013 by the FDA).
• Drug class: Endothelin Receptor Antagonist.
• Mechanism of action: Endothelin Receptor Antagonists.
• Molecular targets: EDNRA, EDNRB, DRD3 and TSPO (5 listed in DrugCentral).
• Indications: Pulmonary arterial hypertension.
• ATC code: C02KX04 (Antihypertensives for pulmonary arterial hypertension).
• Molecular formula: C19H20Br2N6O4S; molecular weight 588.28 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Pulmonary arterial hypertension

Contraindications (1)

• Pregnancy, function

Mechanism & targets

• Mechanism of action (MoA): Endothelin Receptor Antagonists
• Established pharmacologic class: Endothelin Receptor Antagonist

Molecular targets (5)

Target	Gene	Action	Activity
Endothelin-1 receptor	EDNRA	antagonist	IC50 9.30
Endothelin B receptor	EDNRB	antagonist	IC50 6.41
D(3) dopamine receptor	DRD3	unknown	Ki 6.00
Translocator protein	TSPO	unknown	Ki 5.67
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 5.32

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2013-12-20	EMA	—	—
2013-10-18	FDA	—	ACTELION PHARMS LTD	Yes

ATC classification

ATC code	Therapeutic hierarchy
C02KX04	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension
C02KX54	CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dyspnoea	5592.7
Fluid retention	5094.0
Hospitalisation	4885.9
Death	3629.8
Pain in jaw	2681.0
Right ventricular failure	2486.7
Dyspnoea exertional	2305.1
Headache	2092.0
Pulmonary hypertension	2050.6
Hypervolaemia	1861.7
Drug ineffective	1845.7
Transfusion	1703.6

Chemical structure

• Molecular formula: C₁₉H₂₀Br₂N₆O₄S
• Molecular weight: 588.28 g/mol
• CAS number: —
• InChIKey: JGCMEBMXRHSZKX-UHFFFAOYSA-N
• PubChem CID: 16004692

CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Macitentan used for?

DrugCentral lists the following indications for Macitentan: Pulmonary arterial hypertension.

How does Macitentan work?

Macitentan is classified as Endothelin Receptor Antagonists; its molecular targets in DrugCentral include EDNRA (antagonist), EDNRB (antagonist), DRD3 and TSPO.

When was Macitentan first approved?

Macitentan was first approved by the FDA in 2013.

What drug class does Macitentan belong to?

Macitentan is in the Endothelin Receptor Antagonist class.

What is the chemical formula of Macitentan?

Macitentan has the molecular formula C19H20Br2N6O4S and a molecular weight of 588.28 g/mol.

Sources

• DrugCentral drug card 4809 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2103873 — compound record and bioactivity
• PubChem CID 16004692 — chemical identifiers
• DrugBank DB08932 — drug record
• FDA UNII Z9K9Y9WMVL — substance identity
• DailyMed: FDA labels for Macitentan — current prescribing information (label search)
• UniProt P25101 (EDNRA) — target protein
• UniProt P24530 (EDNRB) — target protein
• UniProt P35462 (DRD3) — target protein
• UniProt P30536 (TSPO) — target protein
• UniProt P23975 (SLC6A2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.